Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage ...

VANCOUVER, BC, Dec. 31, 2025 /CNW/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035([1]) , driven by a fundamental shift in cancer ...

This work was supported by the National Natural Science Foundation of China (Grant No. 82373113, XJ), Shenyang Breast Cancer ...

Breast cancer relapse often begins long before it can be seen. Tiny clusters of residual tumor cells may persist after treatment, quietly driving ...

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...

ORLANDO -- A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a common type of childhood leukemia, according to a phase II ...

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

MADISON, Wis., December 11, 2025--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results ...

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma. During the 2025 American Society of Hematology annual meeting, held earlier this month in Orlando, ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...